Skip Navigation

Rheumatology 2008 47(Supplement 5):v18-v20; doi:10.1093/rheumatology/ken267
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Guiducci, S.
Right arrow Articles by Matucci-Cerinic, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guiducci, S.
Right arrow Articles by Matucci-Cerinic, M.
Related Collections
Right arrow Systemic Sclerosis
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

This article appears in the following Rheumatology issue: Update in systemic sclerosis [View the issue table of contents]

Mechanisms of vascular damage in SSc—implications for vascular treatment strategies

S. Guiducci1, O. Distler2, J. H. W. Distler3 and M. Matucci-Cerinic1

1Division of Rheumatology, Department of BioMedicine, AOUC Florence, Florence, Italy, 2Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland and 3Department of Rheumatology and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Nuremberg, Germany.

Correspondence to: S. Guiducci, Department of BioMedicine, Division of Rheumatology, AOUC Florence, Italy Viale Pieraccini 1850139 Florence, Italy. E-mail: serena16{at}libero.it


   Abstract

Vascular abnormalities are a major component of SSc, but little is known about the events or mechanisms that initiate vascular injury and prevent its repair. In SSc, angiogenesis is incomplete or lacking despite the increased expression of a large array of pro-angiogenic factors such as VEGF. Conflicting results have recently been published concerning the presence and role of vasculogenesis and circulating endothelial progenitor cells in SSc. It remains to be established if these endothelial progenitor cells are a marker of endothelial disease or a cause of insufficient vascular repair. Human mesenchymal stem cells (MSCs) may be an alternative source for endothelial progenitor cells, and it has been observed that the angiogenic potential of endothelial-like MSCs is reduced. Other mechanisms of vascular damage include oxidative stress and factors released from activated platelets. In addition, growth factors such as ET-1 and PDGF induce proliferation of vascular smooth muscle cells resulting in intimal thickening. For the development of new therapeutic strategies, it is important to realize that the different vascular pathologies—uncompensated loss of capillaries on one hand and vascular remodelling with a proliferative vasculopathy on the other—might require different treatment approaches.

KEY WORDS: Systemic sclerosis, Vascular damage, Vascular treatment, Endothelial progenitor cell, Mesenchymal stem cell, Endothelial cell, Angiogenesis, Vasculogenesis, Oxidative stress, Platelet activation

Submitted 1 May 2008; Accepted 18 June 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.